2023 ICD-10-CM Diagnosis Code C79.8

Secondary malignant neoplasm of other specified sites

    2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
  • C79.8 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2023 edition of ICD-10-CM C79.8 became effective on October 1, 2022.
  • This is the American ICD-10-CM version of C79.8 - other international versions of ICD-10 C79.8 may differ.
The following code(s) above C79.8 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C79.8:
  • C00-D49
    2023 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C79
    ICD-10-CM Diagnosis Code C79

    Secondary malignant neoplasm of other and unspecified sites

      2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • secondary carcinoid tumors (C7B.-)
    • secondary neuroendocrine tumors (C7B.-)
    Secondary malignant neoplasm of other and unspecified sites
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
ICD-10-CM Codes Adjacent To C79.8
C79.52 Secondary malignant neoplasm of bone marrow
C79.6 Secondary malignant neoplasm of ovary
C79.60 Secondary malignant neoplasm of unspecified ovary
C79.61 Secondary malignant neoplasm of right ovary
C79.62 Secondary malignant neoplasm of left ovary
C79.63 Secondary malignant neoplasm of bilateral ovaries
C79.7 Secondary malignant neoplasm of adrenal gland
C79.70 Secondary malignant neoplasm of unspecified adrenal gland
C79.71 Secondary malignant neoplasm of right adrenal gland
C79.72 Secondary malignant neoplasm of left adrenal gland
C79.8 Secondary malignant neoplasm of other specified sites
C79.81 Secondary malignant neoplasm of breast
C79.82 Secondary malignant neoplasm of genital organs
C79.89 Secondary malignant neoplasm of other specified sites
C79.9 Secondary malignant neoplasm of unspecified site
C80 Malignant neoplasm without specification of site
C80.0 Disseminated malignant neoplasm, unspecified
C80.1 Malignant (primary) neoplasm, unspecified
C80.2 Malignant neoplasm associated with transplanted organ
C81 Hodgkin lymphoma
C81.0 Nodular lymphocyte predominant Hodgkin lymphoma

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.